ECSP22080982A - CRYSTALLINE RET INHIBITOR - Google Patents

CRYSTALLINE RET INHIBITOR

Info

Publication number
ECSP22080982A
ECSP22080982A ECSENADI202280982A ECDI202280982A ECSP22080982A EC SP22080982 A ECSP22080982 A EC SP22080982A EC SENADI202280982 A ECSENADI202280982 A EC SENADI202280982A EC DI202280982 A ECDI202280982 A EC DI202280982A EC SP22080982 A ECSP22080982 A EC SP22080982A
Authority
EC
Ecuador
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
ECSENADI202280982A
Other languages
Spanish (es)
Inventor
Jon Gordon Selbo
Mark Steven Kerr
Shekhar Krishna Viswanath
Douglas Patton Kjell
Jeremy Miles Merritt
Rajni Miglani Bhardwaj
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of ECSP22080982A publication Critical patent/ECSP22080982A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods for preparing this crystalline form.

ECSENADI202280982A 2020-04-17 2022-10-17 CRYSTALLINE RET INHIBITOR ECSP22080982A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19

Publications (1)

Publication Number Publication Date
ECSP22080982A true ECSP22080982A (en) 2023-01-31

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202280982A ECSP22080982A (en) 2020-04-17 2022-10-17 CRYSTALLINE RET INHIBITOR

Country Status (17)

Country Link
EP (1) EP4136090A1 (en)
JP (1) JP2023522012A (en)
KR (1) KR20230002706A (en)
CN (1) CN115916791A (en)
AU (1) AU2021255488A1 (en)
BR (1) BR112022020446A2 (en)
CA (1) CA3174316A1 (en)
CL (1) CL2022002849A1 (en)
CO (1) CO2022014882A2 (en)
CR (1) CR20220520A (en)
DO (1) DOP2022000221A (en)
EC (1) ECSP22080982A (en)
IL (1) IL297212A (en)
MX (1) MX2022012952A (en)
PE (1) PE20230388A1 (en)
TW (1) TW202202501A (en)
WO (1) WO2021211380A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
WO2023114119A1 (en) 2021-12-13 2023-06-22 Loxo Oncology, Inc. Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI812649B (en) * 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI783057B (en) 2017-10-10 2022-11-11 美商絡速藥業公司 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (en) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 Method for preparing RET inhibitor Selpercatinib

Also Published As

Publication number Publication date
TW202202501A (en) 2022-01-16
BR112022020446A2 (en) 2022-11-29
JP2023522012A (en) 2023-05-26
PE20230388A1 (en) 2023-03-06
CN115916791A (en) 2023-04-04
DOP2022000221A (en) 2023-01-15
CA3174316A1 (en) 2021-10-21
CR20220520A (en) 2022-11-15
CO2022014882A2 (en) 2022-10-31
IL297212A (en) 2022-12-01
KR20230002706A (en) 2023-01-05
MX2022012952A (en) 2023-01-11
WO2021211380A1 (en) 2021-10-21
CL2022002849A1 (en) 2023-06-16
AU2021255488A1 (en) 2022-11-10
EP4136090A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CO2022014882A2 (en) crystalline ret inhibitor
DOP2019000163A (en) COMPOUNDS OF 7-PHENYLETHYLAMINE-4H-PYRIMID [4,5-D] [1,3] -OXAZIN-2-ONA AS INHIBITORS OF IDH1 AND IDH2 MUTANTS
CO2019004650A2 (en) Pyrazolo [1,5-a] pyridine compounds substituted as ret kinase inhibitors
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CL2018000119A1 (en) Pyrazolo [1,5-a] pyridine compounds substituted as ret kinase inhibitors.
CL2018002708A1 (en) Methods for inhibition of angiogenesis in a subject in need
ECSP18094983A (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF PLASMA CALICREIN
CR20150450A (en) KINAZOLINIC INHIBITORS OF ACTIVATE MUTED FORMS OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR
CO2021006075A2 (en) Compounds and compositions for the treatment of conditions associated with the activity of nlrp
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
ECSP11010824A (en) TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN.
MX2022007221A (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation.
CL2020000382A1 (en) Compositions of amino acids for the treatment of liver disease.
AR115583A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES AND DISORDERS
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
CL2021000744A1 (en) Methods to treat myeloproliferative disorders
DOP2023000145A (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
CO2021008535A2 (en) Quinoline compounds as tam and met kinase inhibitors
AR104755A1 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE
CL2019000228A1 (en) Joint treatment against types of hematological cancer.
CL2021000580A1 (en) Use of casein kinase 1 inhibitors for the treatment of vascular diseases.
BR112022001393A2 (en) Crystalline form of atr inhibitor and its use
CL2019002808A1 (en) Methods to prevent or treat ophthalmic diseases.
CO2017005357A2 (en) A process for the manufacture of idalopirdine